×
The central target of $76 is the arithmetic mean of 16 recently updated, verified analyst price targets, rounded from roughly $75.50. With the stock trading near $68.50 , reaching $76 implies an upside of about 11% —a modest move by equity-market standards.
Oscar Health (OSCR) traded roughly flat over the trailing 30 days, edging about 2% lower to the low-$32 range, even after a standout third-quarter report. Third-quarter 2026 EPS came in at $0.49, well above consensus, on revenue of approximately $5.14 billion, up roughly 70% year over year.
Centene (CNC) shares have traded near $68.50, up roughly 5% over the trailing 30 days, with the move reflecting broad managed-care momentum rather than a single event. The stock has climbed about 66% year to date, recovering sharply from 2025, when elevated medical costs forced management to withdraw its earnings guidance.
Scale and scope diverge sharply: UNH is a diversified healthcare giant spanning insurance and health services, while MOH is a focused government-programs managed care provider. Cost management is the defining contrast: UnitedHealth's medical care ratio (MCR) has improved in recent quarters, while Molina's MCR remains elevated amid Medicaid margin pressure.
The central UNH stock price target examined here is $480 , roughly 22% above the latest verified price near $394. This target is the arithmetic mean of roughly a dozen recent, individually verifiable analyst price targets, rounded to a clean level (about $477 before rounding); the broader S&P Global-polled average of 26 analysts is $476.64.
UNH is the stock ticker for UnitedHealth Group Incorporated, one of the largest healthcare companies in the world by revenue. The company operates through two main businesses: UnitedHealthcare , a health insurance and benefits arm, and Optum , a diversified health services platform.
META (Meta Platforms) is delivering rapid revenue growth and AI momentum but faces negative free cash flow (FCF, cash left after capital spending), heavy capital expenditures (capex), and legal headwinds. UNH (UnitedHealth Group) is executing a margin-recovery turnaround, with improving medical cost ratios and consistent earnings beats, but faces slower revenue growth and regulatory scrutiny.
UNH is a single large-cap managed-care and health-services company, while VHT is a diversified healthcare exchange-traded fund (ETF) holding more than 400 healthcare stocks. On relative performance, UNH has shown stronger recent momentum, while VHT offers broader sector exposure and lower single-name risk.
Humana reported a third quarter 2026 adjusted loss of $0.70 per share, narrower than the roughly $1.00 consensus loss and down from adjusted earnings of $3.24 per share a year earlier. Revenue climbed about 26% year over year to $41.16 billion, topping analyst estimates, driven by Medicare membership growth and higher premiums.
Centene (CNC) fell during regular trading hours, dropping from a prior close of $74.17 to roughly $69.41, a decline of -6.42%. The drop extends profit-taking after Centene surged +12.6% on Nov. 4, when Democratic midterm wins lifted expectations for Medicaid and ACA subsidy support; no new company-specific news drove today's move.
OSCR dropped during regular market hours, sliding from a $33.18 prior close to roughly $30.58, a -7.84% decline. The move extends a post-earnings "sell-the-news" unwind: a strong Q3 beat (GAAP EPS $0.49 vs. an expected loss, $5.14B revenue, and a third full-year guidance raise) spiked shares to a 52-week high on Nov 4, and traders are now taking profits after a ~28% run since August.
The Cigna Group reported third quarter 2026 adjusted earnings per share (EPS) of $7.98 , exceeding Wall Street's consensus estimate of roughly $7.50. Total revenue rose 6% year over year to $73.7 billion , slightly above analyst expectations of about $72.7 billion.
Progyny (PGNY) shares climbed roughly 32.8% over the last 30 days, rising from about $25.91 on October 6, 2026, to around $34.40, touching a fresh 52-week high in the process. The catalyst was a record third quarter and, more importantly, the strongest selling season in the company's history, headlined by 1.3 million new covered lives.
Progyny (PGNY) rallied from a prior close of $30.10 to $33.80, a gain of +12.29%, during regular market hours on Wednesday. The surge extends a post-earnings rally after Q3 results (reported Nov. 4) beat estimates, highlighted by a record selling season adding 1.3 million covered lives and 85+ new clients, plus raised full-year guidance.
Progyny reported third quarter 2026 revenue of $341.3 million , up 8.9% year over year and essentially in line with consensus estimates of $340.9 million. Adjusted earnings per share (EPS) came in at $0.52 , about 2% above the analyst consensus estimate of $0.51.
Clover Health reported third-quarter 2026 revenue of $759.3 million , up 52.9% year over year and above analyst consensus estimates of roughly $740 million. GAAP (generally accepted accounting principles) earnings came in at $0.01 per share , ahead of consensus expectations of approximately breakeven, and flipped from a net loss of $24.4 million a year earlier to net income of $6.4 million.
CVS Health reported third-quarter 2026 total revenues of $108.4 billion , up 5.4% year over year and above the consensus estimate of roughly $104.7 billion. Adjusted earnings per share (EPS, or profit per share excluding one-time items) came in at $2.09 , topping the consensus estimate of $1.65, while GAAP diluted EPS (the standard accounting measure) was $1.68 .
CVS shares dropped -12.36%, from a $91.41 prior close to $80.11, during regular market hours. The decline followed CVS's announcement that it will split into two publicly traded companies by H1 2028, separating its ~9,000 retail pharmacies from the Aetna and Caremark businesses.
CVS Health shares fell from a previous close of $91.41 to $81.07 during regular trading, a drop of -11.31%. The decline followed CVS's announcement that it will split into two independent public companies, separating its retail pharmacies from the Aetna and Caremark insurance/PBM businesses, with investors balking at the surprise breakup's multi-year execution risk and regulatory backdrop.
CVS Health (CVS) dropped from a previous close of $91.41 to $81.89, a -10.42% decline during regular market hours. The selloff followed CVS's announcement that it will split into two publicly traded companies—separating its Aetna insurance and Caremark PBM business from its roughly 9,000 retail pharmacies—alongside a Q3 earnings beat and raised guidance; investors sold the news on multi-year execution risk and uncertainty.